An Open-Label, Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KBP-5074 in Healthy Subjects With a Separate Panel in Subjects With Mild to Moderate Renal Impairment

Trial Profile

An Open-Label, Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KBP-5074 in Healthy Subjects With a Separate Panel in Subjects With Mild to Moderate Renal Impairment

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Mar 2017

At a glance

  • Drugs KBP 5074 (Primary)
  • Indications Diabetic nephropathies; Renal hypertension
  • Focus Adverse reactions
  • Sponsors KBP Biosciences
  • Most Recent Events

    • 07 Mar 2017 Planned End Date changed from 1 Sep 2016 to 1 Jul 2017.
    • 30 Jun 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Sep 2016.
    • 30 Jun 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top